ImmuCell Announces Preliminary Q3 Revenue Of $6M Up From $5.4M YoY
Portfolio Pulse from Benzinga Newsdesk
ImmuCell Corporation (Nasdaq: ICCC) reported preliminary Q3 2024 revenue of $6 million, up 11% from $5.4 million YoY. The company also reported significant revenue growth for the nine- and twelve-month periods, with a strong order backlog of $7.3 million, indicating robust demand.
October 08, 2024 | 8:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmuCell's preliminary Q3 2024 revenue increased by 11% YoY to $6 million, with strong growth in nine- and twelve-month periods. The company has a $7.3 million order backlog, indicating strong demand.
The 11% YoY revenue growth and significant backlog suggest strong demand and positive business momentum, likely boosting investor confidence and short-term stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100